Smartwatch data helps track Parkinson's symptoms between clinic visits
A new monitoring tool leverages Apple Watch sensors to provide clinicians with continuous insights into Parkinson's tremors and involuntary movements, aiming to bridge the gap between sparse hospital appointments and daily life.
People living with Parkinson's disease often face a diagnostic blind spot between clinic visits, where symptoms can fluctuate significantly throughout the day. A new monitoring tool developed by Kneu Health addresses this gap by integrating continuous data from Apple Watches with structured smartphone assessments. This approach allows healthcare providers to observe how tremors and other motor symptoms manifest in real-world settings, rather than relying solely on brief check-ups in a clinical environment.
The system is designed to capture passive movement data that traditional methods miss. By combining this with active tests for voice, balance, and reaction time, the platform offers a more comprehensive view of a patient’s condition. According to reports from GN technics/mobile (en-US), the tool has been adopted by a significant portion of eligible patients in the U.K., with clinicians noting that the consolidated data helps in making more personalized treatment decisions.
Continuous monitoring captures daily symptom fluctuations
Parkinson's disease is characterized by the loss of nerve cells that produce dopamine, leading to motor symptoms like tremor and stiffness. These symptoms are not static; they can vary based on time of day, medication timing, and physical activity. A standard clinic visit typically lasts only a few minutes, which is often insufficient to capture the full range of a patient's motor challenges. The new tool aims to resolve this by recording data continuously, providing a timeline of symptoms that reflects the patient's actual daily experience.
The platform specifically tracks dyskinesia, which refers to involuntary movements that can occur as a side effect of long-term Parkinson's medications. By monitoring these movements passively, the system helps doctors distinguish between symptoms caused by the disease itself and those resulting from treatment. This distinction is critical for adjusting medication dosages effectively, as over-medicating can lead to severe involuntary movements, while under-medicating leaves core symptoms unmanaged.
Integration of active and passive data streams
The tool does not rely on a single data source. Instead, it merges passive data collected from the Apple Watch with active assessments conducted on a smartphone. The active component involves guided tests where users perform specific movements or speak to evaluate voice quality and cognitive function. This dual approach ensures that the data is both comprehensive and contextually rich. Machine learning algorithms analyze these inputs to identify patterns that might signal a change in the disease's progression.
For clinicians, this integration means receiving a unified dashboard rather than disjointed reports. One patient in the U.K. noted that having all information in one place was helpful, stating that the more data their clinician could access, the better. This centralized view supports more informed decision-making, allowing doctors to tailor treatment plans with greater precision. The system is registered with the U.K. regulatory agency and has received clearance from the U.S. Food and Drug Administration for use in both markets.
Accessibility and regulatory approval for broad use
The availability of this tool is expanding rapidly. In the U.K., where it was first introduced, 79% of eligible patients began using the feature within two weeks. This high adoption rate suggests that the interface is accessible enough for people with motor challenges to use independently. The platform is currently operational across ten National Health Service organizations, indicating that healthcare systems are recognizing its value in improving care continuity.
However, there are trade-offs to consider. The reliance on Apple Watch hardware limits the tool's availability to users of that specific ecosystem, potentially excluding patients who use other smartwatch brands or wearables. Additionally, while the data provides a more complete picture, it requires clinicians to interpret continuous streams of information, which adds complexity to their workflow. Despite these challenges, the tool represents a significant step toward personalized medicine, offering a way to monitor chronic conditions more effectively without requiring frequent hospital visits.
